ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta

American Journal of Nephrology

Volumn 32, Issue 3, 2010, Pages 201-211

  Vaziri, Nosratola D ^a   Bai, Yongli ^a   Yuan, Jun ^a   Said, Hannah L ^a   Sigala, Whitney ^a   Ni, Zhemin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammatory agents; Atherosclerosis; Cardiovascular disease; Chronic kidney disease; Dyslipidemia; End stage renal disease; High density lipoprotein cholesterol; Inflammation; Oxidative stress; Reverse cholesterol transport

Indexed keywords

3 NITROTYROSINE; APOLIPOPROTEIN A1; ARACHIDONATE 12 LIPOXYGENASE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; L4F; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PEPTIDE DERIVATIVE; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERITIS; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; THORACIC AORTA; UREMIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; AORTA, THORACIC; APOLIPOPROTEIN A-I; ARACHIDONATE 12-LIPOXYGENASE; ARTERITIS; ATHEROSCLEROSIS; CHEMOKINE CCL2; CYCLOOXYGENASE 2; MALE; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PEPTIDES; PEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; TYROSINE; UP-REGULATION; UREMIA;

EID: 77954556946     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316479     Document Type: Article

References (52)

1. Excerpts from the United States Renal Data System 2005 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2006; 47:S1-S286.
2. Go AS, Chertow GM, Fan D, McCulloch C, Hsu C: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Kovesdy CP, Trivedi BK, Anderson JE: Associations of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study. Adv Chronic Kidney Dis 2006; 13: 183-188.
4. Muntner P, He J, Astor BC, Folsom AR, Coresh JI: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-538.
5. Vaziri ND: Oxidative stress in chronic renal failure: the nature, mechanism and consequences. Semin Nephrol 2004; 24: 469-473.
6. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou X: Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol Renal Physiol 1998; 274:F642-F649.
7. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim R: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
8. McCullough PA: Why is chronic kidney disease the 'spoiler' for cardiovascular outcomes? J Am Coll Cardiol 2003; 41: 725-728.
9. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337.
10. Vaziri ND: Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38:S74-S79.
11. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006; 290: 262-272.
12. Hansson GK, Robertson AK, Söderberg- Nauclér C: Inflammation and atherosclerosis. Annu Rev Pathol 2006; 1: 297-329.
13. Wilensky RL, Hamamdzic D: The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol 2007; 22: 545-551.
14. Gleissner CA, Leitinger N, Ley K: Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis. Hypertension 2007; 50: 276-283.
15. Navab M, Anantharamaiah GM, Reddy ST, et al: Mechanisms of disease: proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-511.
16. Vaziri ND, Liang K: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996; 50: 1928-1935.
17. Vaziri ND, Wang XQ, Liang K: Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol Renal Physiol 1997; 273:F925-F930.
18. Vaziri ND, Liang K: Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 1997; 51: 913-919.
19. Sato T, Liang K, Vaziri ND: Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int 2003; 64: 1780-1786.
20. Kim C, Vaziri ND: Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 2005; 67: 1028-1032.
21. Davidson MH, Toth PP: High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007; 100:n32-n40.
22. Calabresi L, Gomaraschi M, Franceschini G: Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003; 23: 1724-1731.
23. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M: Protective effect of high-density lipoprotein-associated paraxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
24. Feig JE, Shamir R, Fisher EA: Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 2008; 9: 196-203.
25. Vaziri ND: Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 2009; 22: 644-651.
26. Vaziri ND, Navab M, Fogelman AM: HDL metabolism and activity in chronic kidney disease. Nature Rev Nephrol 2010 (in press).
27. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-1466.
28. Liang K, Kim C, Vaziri ND: HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 2005; 288:F539-F544.
29. Vaziri ND, Liang K, Parks JS: Downregulation of lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int 2001; 59: 2192-2196.
30. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG: Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996; 97: 2167-2173.
31. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of HDL in chronic kidney disease. Transl Res 2009; 153: 77-85.
32. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman A, Navab M: HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007; 72: 1149-1156.
33. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M: In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an ApoA-1 mimetic peptide. Kidney Int 2009; 76: 437-444.
34. Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L, Beaudet A, Chan L: Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726-2732.
35. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Puré E, Rader DJ: Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 816-822.
36. Calabresi L, Sirtori CR, Paoletti R, Franceschini G: Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006; 8: 163-167.
37. Yu R, Yekta B, Vakili L, Gharavi N, Navab M, Marelli D, Ardehali A: Proatherogenic highdensity lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 2008; 10: 171-176.
38. Navab M, Anantharamaiah GM, Reddy ST, et al: Oral D-4F causes formation of pre-high-density lipoprotein and improves highdensity lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109: 3215-3220.
39. Li X, Chyu KY, Faria Neto JR, et al: Differential effects of apolipoprotein A-I mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110: 1701-1705.
40. Shah PK, Chyu KY: Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med 2005; 15: 291-296.
41. Ou J, Ou Z, Jones DW, et al: L4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003; 107: 2337-2341.
42. Ou J, Wang J, Xu H, et al: Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I doubleknockout mice on Western diet. Circ Res 2005; 97: 1190-1197.
43. Navab M, Anantharamaiah GM, Fogelman AM: The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med 2008; 18: 61-66.
44. Vaziri ND, Kim H, Moradi H, Farmand F, Navab K, Navab M, Hama S, Fogelman AM, Quiroz Y, Rodriguez-Iturbe B: Amelioration of nephropathy with ApoA-1 mimetic peptide in ApoE-deficient mice. Nephrol Dial Transplant 2010 (in press).
45. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM: Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 2010; 30: 164-168.
46. Kim HJ, Vaziri ND: Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298:F662-F671.
47. Kim HJ, Moradi H, Vaziri ND: Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol 2009; 296:F1297-F1306.
48. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ: Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006; 15: 265-279.
49. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
50. Agirbasli M: Pivotal role of plasminogen-activator inhibitor-1 in vascular disease. Int J Clin Pract 2005; 59: 102-106.
51. Heinecke JW: The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Atheroscler Rep 2007; 9: 249-251.
52. Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND: Reverse cholesterol transport pathway in experimental chronic kidney disease. Am J Nephrol 2009; 30: 147-154.